GDUFA IV: US FDA Worries About Revenue Shortfalls, Industry Does Not

 
• By Derrick Gingery
  
The FDA warned industry about the consequences of continued under-collection of GDUFA fee revenue. (Shutterstock)

More from Generics

More from Products